Complications of Antiphospholipid Antibody Syndrome (APAS)
Antiphospholipid antibody syndrome causes life-threatening thrombotic complications (arterial and venous), pregnancy morbidity with high fetal loss rates, and potentially catastrophic multi-organ failure, with lupus anticoagulant conferring the highest risk for adverse outcomes.
Major Thrombotic Complications
Vascular Thrombosis
APAS drives both arterial and venous thrombosis through antibody-mediated cellular activation and inflammatory pathways 1. The syndrome manifests as:
- Venous thromboembolism: Deep vein thrombosis and pulmonary embolism represent the most common thrombotic events
- Arterial thrombosis: Stroke is particularly prevalent, especially in young adults (<50 years), where the association with antiphospholipid antibodies is strongest 2
- Multi-organ thrombosis: The full syndrome includes venous and arterial occlusive disease affecting multiple organs, often accompanied by livedo reticularis 2
Critical point: Patients with both lupus anticoagulant and anticardiolipin antibodies demonstrate significantly higher event rates (31.7%) compared to antibody-negative patients (24.0%), though this represents composite outcomes including death, stroke, MI, and systemic thrombo-occlusive events 2.
Microvascular Complications
Beyond large vessel thrombosis, APAS causes microvascular injury that can manifest as:
- Diffuse alveolar hemorrhage: A severe, life-threatening pulmonary complication 1
- Microvascular thrombosis: Now recognized in the 2023 ACR/EULAR classification criteria as a distinct clinical feature 3
Pregnancy-Related Complications
Obstetric Morbidity
Antiphospholipid antibodies represent a major risk factor for pregnancy loss and adverse pregnancy outcomes, with lupus anticoagulant conveying the greatest risk: RR 12.15 (95% CI 2.92-50.54, P=0.0006) for adverse pregnancy outcomes 4.
Specific pregnancy complications include:
- Recurrent pregnancy loss: Three or more miscarriages before 10 weeks gestation 5
- Fetal death: Late pregnancy losses (≥10 weeks) due to placental insufficiency 6
- Preeclampsia: APAS patients face substantially elevated risk regardless of clinical history 4
- Placental insufficiency: Leading to intrauterine growth restriction and premature delivery
Treatment reality: Even with standard therapy (low-dose aspirin plus prophylactic heparin/LMWH), pregnancy loss still occurs in 25% of obstetric APAS pregnancies 4, 7. Patients positive for lupus anticoagulant have at least a 30% likelihood of adverse pregnancy outcomes despite treatment 6.
Postpartum Thrombotic Risk
Pregnancy increases thrombosis risk through hemostatic and anatomic factors. Women with obstetric APAS require prophylactic-dose anticoagulation for 6-12 weeks postpartum 7.
Renal Complications
APAS-related kidney disease occurs in approximately 3% of patients 8. Manifestations include:
Macrovascular Renal Events
- Renal artery stenosis: The most common kidney-related complication
- Renal artery thrombosis
- Renal infarction
Microvascular Renal Disease
- APAS nephropathy: The predominant microvascular complication
- Clinical presentations: Range from hematuria and non-nephrotic proteinuria to severe hypertension
Catastrophic Antiphospholipid Syndrome (CAPS)
CAPS represents the most severe manifestation, presenting as fulminant multi-organ failure with widespread microvascular thrombosis 8. This life-threatening condition requires:
- Immediate recognition as distinct from preeclampsia (which it may initially mimic) 6
- Aggressive treatment with pulsed corticosteroids, plasmapheresis, and intravenous immunoglobulins 8
Cardiac Complications
The 2023 ACR/EULAR criteria now recognize cardiac valve involvement as a distinct clinical feature, broadening the recognized spectrum of APAS manifestations 3.
Hematologic Complications
Thrombocytopenia is now included in the updated classification criteria as a recognized clinical domain 3.
Risk Stratification
Highest Risk Patients
Triple-positive patients (lupus anticoagulant + anticardiolipin + anti-β2GPI antibodies) face the greatest risk for thrombotic and obstetric complications 4, 9. Additional high-risk features include:
- Strongly positive lupus anticoagulant results
- History of thrombosis
- Concurrent systemic lupus erythematosus
- Younger age in aPL-positive women 4
Laboratory Hierarchy
Among antiphospholipid antibodies, lupus anticoagulant conveys the greatest risk for adverse outcomes, significantly exceeding the risk associated with anticardiolipin or anti-β2GPI antibodies alone 4.
Common Pitfalls
Do not confuse classification criteria with clinical diagnosis. The 2023 ACR/EULAR criteria emphasize 99% specificity at the expense of 84% sensitivity 3. Many patients with genuine antiphospholipid antibody-related conditions may not meet classification criteria but still require appropriate management to prevent thrombotic or obstetric events 3.
Patients with low-titer antibodies, isolated IgM isotype antibodies, or recurrent early miscarriage without preeclampsia may not meet current classification criteria but still face real clinical risks requiring individualized assessment 6.